The production plant is being built on an area of 5 hectares with dedicated expandable clean room space
Following growth in the the drug delivery devices market, Nemera is extending its manufacturing capabilities in Szczecin, Poland.
Construction of the facility is a next step after the strategic acquisition of Copernicus in 2020 to bolster production capabilities, R&D expertise and extend the company’s product offering. The foundation stone of the manufacturing site was laid during a ceremony in the presence of company management, state and local authorities, investment partners, academics and other stakeholders.
“This is a historic moment for us. The new facility, which is a first block of a three-fold masterplan, will support Nemera’s overall forecasted growth as well as contribute to infrastructure development in the region. More importantly, it’ll help us serve more customers and patients in and around these markets.” said Marc Hämel, CEO of Nemera.
Sébastian Perrier, COO of Nemera, added: “I am very pleased to be here today. Our new facility will be capable of developing prototypes, produce small series for clinical batches as well as large scale automated volumes. Initially focused on injection devices, we’ll extend manufacturing and development across different delivery routes.”
The production plant is being built on an area of 5 hectares with dedicated expandable clean room space (starting with 3400 sqm) for injection and assembly of existing and new devices. The manufacturing facility will also harbour research and development resources to support design and prototyping of devices in an integrated way. The entire infrastructure will be BREEAM certified.
“We’re excited to reveal our new manufacturing facility, the first of its kind in Poland, by next fall. We want to provide the best possible working environment for our people.” said Alberto Lozano, Director of Nemera Szczecin.